Observational studyAsian journal of andrology2026
Excellent long-term device survival of inflatable penile prosthesis over 27 years.
Observational study in Asian journal of andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Update on penile prosthesis.Asian journal of andrology · 2026Article
- Infection following inflatable penile prosthesis placement: a real-world comparison of device selection and patient characteristics.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aimed to assess the long-term device survival of a 3-piece inflatable penile prosthesis (PP) in patients with erectile dysfunction (ED). This retrospective observational longitudinal study involved patients with drug-refractory ED who underwent primary 3-piece inflatable PP implantation at a single center from 1992 to 2019. The outcomes included complications of various inflatable PP models, and Kaplan-Meier analysis was used to estimate the probability of PP survival. Of the total 426 patients, 140 (32.9%) were implanted in the period of 1992-2000, 128 (30.0%) in the period of 2001-2008, and 158 (37.1%) in the period of 2009-2019. The PP used in the study included AMS 700 CX (62.0%, n = 264), AMS 700 CXR (7.7%, n = 33), AMS Ultrex Plus (10.3%, n = 44), and Alpha I (20.0%, n = 85). The overall complication rate was 28.2% (120/426), and the majority happened after 6 months. The causes of device removal included mechanical failure (11.0%, n = 47), infection (3.9%, n = 17), cylinder extrusion (6.3%, n = 27), and unspecified (0.2%, n = 1). Of the total mechanical failures ( n = 47), 18 (38.3%) occurred in the cylinders, 10 (21.3%) occurred in the pump, 7 (14.9%) occurred in the reservoir, 6 (12.8%) occurred in the connections, and 6 (12.8%) were nonspecific. Global average survival rates of the PP at 1 year, 5 years, 10 years, and 15 years were 96.2%, 86.7%, 77.5%, and 58.7%, respectively. The 3-piece inflatable PP has an excellent device survival rate at 5 years and 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.